組織工学皮膚代替物市場：規模、セグメント別、シェア、法規制、償還、手技、2033年までの予測

組織工学皮膚代替物の使用は、慢性創傷を治癒するための代替療法を提供し、従来の治療法と比較して優れた有効性と、場合によっては同等の費用対効果を示します。その主な目的は、損傷した組織や臓器を最終的に修復、維持、改善できる機能的な構築物を利用し、回復過程や生存の可能性を向上させることです。

組織工学皮膚代替物は、ドナー皮膚移植片の供給不足を補う効率的な方法です。この代用皮膚は、損傷部位を体液の喪失や汚染から保護し、創傷部位のサイトカインや成長因子の放出を促進し、創傷治癒過程を促進することができます。また、治癒中の創床を一時的に保護する役割も果たします。

治癒が遅れる表皮創傷は、死亡を含め患者の健康にいくつかのリスクをもたらす可能性があります。さらに深いレベルでは、深刻な慢性創傷の形成につながる危険性もあります。代用皮膚は、治癒を促進するのに必要な細胞、可溶性メディエーター、細胞外マトリックス材料を提供することで、難治性の創傷の回復に有望です。慢性創傷の治療に費やされる費用は、米国では平均して年間約320億米ドルに上る。これらの慢性創傷の90％は、糖尿病、静脈うっ滞、放射線、麻痺などの結果です。

当レポートは、世界の組織工学皮膚代替物市場について詳細に考察し、市場における競合情勢、SWOT分析、2033年までの市場予測、COVID-19の影響、地域、国別の動向などを提供しています。

目次

現在上市されている組織工学皮膚代替物と競合情勢

• 主要な業界動向の洞察
• 組織工学皮膚代替物のセグメント別総市場収益と2015年～2033年の市場展望
• 個数、平均販売価格、市場価値に関する詳細データ

世界、地域、国別の洞察

• 組織工学皮膚代替物市場のSWOT分析
• 組織工学皮膚代替物市場に関する競合力学の洞察と動向
• 国別の医療制度の概要
• 国別の償還政策
• 国別の医療技術に関する規制の状況

Abstract

Tissue Engineered - Skin Substitutes Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033 is built to visualize quantitative market trends within Wound Care Management therapeutic area.

The model discusses in detail the impact of COVID-19 on Tissue Engineered - Skin Substitutes market for the year 2020 and beyond. The use of skin substitutes provides an alternative therapy to heal chronic wounds showing superior efficacy and, in some cases, similar cost-effectiveness compared to traditional treatments. The main objective is to make use of functional construct that can ultimately restore, maintain and improve damaged tissues and organs through improving the recovery process and chances of survival.

Tissue-engineered skin substitutes represent an efficient way of meeting the deficiency in donor-skin-graft supplies. They are able to protect damaged regions from fluid loss and contamination and promote release of cytokines and growth factors at the wound site, accelerating the wound-healing processes. They also act as a temporary protective cover of the wound bed during healing.

Epidermal wounds which show delayed healing process can lead to several risks to patient's health including death. A deeper level risk of these can lead to serious chronic wound formation. Skin substitutes have lead to promising recovery practices for refractory wounds by providing cells, soluble mediators, and extracellular matrix materials needed to stimulate healing. On average, it is observed that the cost spent for chronic wound treatments comes to around $32B in the US annually. 90% of these chronic wounds are a result of diabetes, venous stasis, radiation or paralysis.

Each of the covered 39 country's color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.

Key Inclusions of the market model are -

Currently marketed Tissue Engineered - Skin Substitutes and evolving competitive landscape -

• Insightful review of the key industry trends.
• Annualized total Tissue Engineered - Skin Substitutes market revenue by segment and market outlooks from 2015-2033.
• Market level data on units, average selling prices and market values.

Global, Regional and Country level market specific insights -

• Qualitative market specific information is available with global trends further broken down into regional trends. In addition, GlobalData analysts provide unique country specific insights on the market.
• SWOT analysis for Tissue Engineered - Skin Substitutes market.
• Competitive dynamics insights and trends provided for Tissue Engineered - Skin Substitutes market.

Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.

• Country specific overview of the healthcare system.
• Country specific reimbursement policies.
• Country specific medtech regulatory landscape.

Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies covered - Integra LifeSciences Corp, LifeNet Health Inc, MiMedx Group Inc, Organogenesis Holdings Inc, Smith & Nephew Plc, Allergan Ltd, and Others.

Countries covered - United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina, and Chile.

Scope

This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -

• CMO executives who must have deep understanding of the Tissue Engineered - Skin Substitutes marketplace to make strategic planning and investment decisions.
• Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
• Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to Buy

The model will enable you to -

• Understand the impact of COVID-19 on Tissue Engineered - Skin Substitutes market.
• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving Tissue Engineered - Skin Substitutes market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Tissue Engineered - Skin Substitutes market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Track device sales in the global and country-specific Tissue Engineered - Skin Substitutes market from 2015-2033.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.